Ham­mered by crit­ics, NewLink strikes back with pos­i­tive PhII in­dox­i­mod da­ta — and shares rock­et up

Few biotechs have in­spired the kind of love-hate re­la­tion­ship that NewLink Ge­net­ics $NLNK seems to pro­voke among the bulls and bears in the biotech in­vest­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.